Literature DB >> 10072492

Mucosal immunity to influenza without IgA: an IgA knockout mouse model.

I N Mbawuike1, S Pacheco, C L Acuna, K C Switzer, Y Zhang, G R Harriman.   

Abstract

IgA knockout mice (IgA-/-) were generated by gene targeting and were used to determine the role of IgA in protection against mucosal infection by influenza and the value of immunization for preferential induction of secretory IgA. Aerosol challenge of naive IgA-/- mice and their wild-type IgA+/+ littermates with sublethal and lethal doses of influenza virus resulted in similar levels of pulmonary virus infection and mortality. Intranasal and i.p. immunization with influenza vaccine plus cholera toxin/cholera toxin B induced significant mucosal and serum influenza hemagglutinin-specific IgA Abs in IgA+/+ (but not IgA-/-) mice as well as IgG and IgM Abs in both IgA-/- and IgA+/+ mice; both exhibited similar levels of pulmonary and nasal virus replication and mortality following a lethal influenza virus challenge. Monoclonal anti-hemagglutinin IgG1, IgG2a, IgM, and polymeric IgA Abs were equally effective in preventing influenza virus infection in IgA-/- mice. These results indicate that IgA is not required for prevention of influenza virus infection and disease. Indeed, while mucosal immunization for selective induction of IgA against influenza may constitute a useful approach for control of influenza and other respiratory viral infections, strategies that stimulate other Igs in addition may be more desirable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072492

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Where do IgA plasma cells in the gut come from?

Authors:  S J C Golby; J Spencer
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection.

Authors:  Taishi Onodera; Yoshimasa Takahashi; Yusuke Yokoi; Manabu Ato; Yuichi Kodama; Satoshi Hachimura; Tomohiro Kurosaki; Kazuo Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

5.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

6.  Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity.

Authors:  Daniel N Wolfe; Girish S Kirimanjeswara; Eric T Harvill
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  An attenuated duck plague virus (DPV) vaccine induces both systemic and mucosal immune responses to protect ducks against virulent DPV infection.

Authors:  Juan Huang; Renyong Jia; Mingshu Wang; Bing Shu; Xia Yu; Dekang Zhu; Shun Chen; Zhongqiong Yin; Xiaoyue Chen; Anchun Cheng
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

8.  Role of immunoglobulin A in protection against reovirus entry into Murine Peyer's patches.

Authors:  K J Silvey; A B Hutchings; M Vajdy; M M Petzke; M R Neutra
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 9.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

10.  Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis.

Authors:  Saúl Rojas-Hernández; Marco A Rodríguez-Monroy; Rubén López-Revilla; Aldo A Reséndiz-Albor; Leticia Moreno-Fierros
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.